chronic graft-versus-host disease in patients who have undergone donor stem cell transplant

Conditions: Cancer

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to chronic graft-versus-host disease in patients who have undergone donor stem cell transplant. purpose: this phase i trial is studying chronic graft-versus-host disease in patients who have undergone donor stem cell transplant.

objectives: * to determine and define the biological basis of different subtypes of chronic graft-vs-host disease using a targeted single nucleotide polymorphisms approach in patients who have undergone allogeneic stem cell transplantation. outline: two important aspects of the methodologies that will be employed for the analysis of snps associated with gvhd are throughput efficiency to be able to perform the assays on a reasonable number of samples as well as having the ability to add or remove snps to the assay panel. while a genome-wide association study to identify variants associated with gvhd would offer an unbiased approach, our patient cohort size would not allow significant statistical power in the study. therefore, a more targeted approach using two established technologies is proposed. the sequenome assay uses the unique combination of a single-base primer extension assay incorporating one of four modified nucleotides. the four modified nucleotides each have a unique mass that allows them to be distinguished from one another using mass spectrometry. each snp is determined analyzing the primer extension product from a pcr amplicon that surrounds the snp of interest. the development of each assay involves designing flanking pcr primers and an internal extension assay using web-based software provided by sequenome. the assays can be designed to analyze up to 30 snps in a single reaction, providing a customizable, efficient and high-throughput assay for snps of interest.

Eligibility criteria:
disease characteristics: * underwent prior matched related or unrelated allogeneic stem cell transplantation (sct) * presence or absence of chronic graft-vs-host disease after day 100 and alive after day 180 post-transplantation * no t-cell depleted sct, cord blood transplantation, mismatched allogeneic transplantation, or autologous transplantation * available recipient and donor dna (samples collected from the vanderbilt university or the fred hutchinson cancer center tissue bank) patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: graft versus host disease stage iii adult burkitt lymphoma stage iii adult diffuse large cell lymphoma stage iii adult diffuse mixed cell lymphoma stage iii adult diffuse small cleaved cell lymphoma stage iii adult hodgkin lymphoma stage iii adult immunoblastic large cell lymphoma stage iii adult lymphoblastic lymphoma stage iii grade 1 follicular lymphoma stage iii grade 2 follicular lymphoma stage iii grade 3 follicular lymphoma stage iii mantle cell lymphoma stage iii marginal zone lymphoma stage iii small lymphocytic lymphoma stage iv adult burkitt lymphoma stage iv adult diffuse large cell lymphoma stage iv adult diffuse mixed cell lymphoma stage iv adult diffuse small cleaved cell lymphoma stage iv adult hodgkin lymphoma stage iv adult immunoblastic large cell lymphoma stage iv adult lymphoblastic lymphoma stage iv grade 1 follicular lymphoma stage iv grade 2 follicular lymphoma stage iv grade 3 follicular lymphoma stage iv mantle cell lymphoma stage iv marginal zone lymphoma stage iv small lymphocytic lymphoma recurrent adult burkitt lymphoma recurrent adult diffuse large cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse small cleaved cell lymphoma recurrent adult hodgkin lymphoma recurrent adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma recurrent childhood large cell lymphoma recurrent childhood lymphoblastic lymphoma recurrent childhood small noncleaved cell lymphoma recurrent cutaneous t-cell non-hodgkin lymphoma recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma recurrent mantle cell lymphoma recurrent marginal zone lymphoma recurrent small lymphocytic lymphoma recurrent/refractory childhood hodgkin lymphoma recurrent mycosis fungoides/sezary syndrome nodal marginal zone b-cell lymphoma splenic marginal zone lymphoma noncontiguous (nc) stage ii adult burkitt lymphoma nc stage ii adult diffuse large cell lymphoma nc stage ii adult diffuse mixed cell lymphoma nc stage ii adult diffuse small cleaved cell lymphoma nc stage ii adult immunoblastic large cell lymphoma nc stage ii adult lymphoblastic lymphoma nc stage ii grade 1 follicular lymphoma nc stage ii grade 2 follicular lymphoma nc stage ii grade 3 follicular lymphoma nc stage ii mantle cell lymphoma nc stage ii marginal zone lymphoma nc stage ii small lymphocytic lymphoma accelerated phase chronic myelogenous leukemia adult acute lymphoblastic leukemia in remission adult acute myeloid leukemia in remission adult acute myeloid leukemia with 11q23 (mll) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) atypical chronic myeloid leukemia, bcr-abl negative blastic phase chronic myelogenous leukemia childhood acute lymphoblastic leukemia in remission childhood acute myeloid leukemia in remission childhood chronic myelogenous leukemia chronic myelomonocytic leukemia chronic phase chronic myelogenous leukemia juvenile myelomonocytic leukemia recurrent adult acute lymphoblastic leukemia recurrent adult acute myeloid leukemia recurrent childhood acute lymphoblastic leukemia recurrent childhood acute myeloid leukemia refractory chronic lymphocytic leukemia refractory hairy cell leukemia relapsing chronic myelogenous leukemia secondary acute myeloid leukemia stage iii chronic lymphocytic leukemia stage iv chronic lymphocytic leukemia childhood myelodysplastic syndromes chronic eosinophilic leukemia primary myelofibrosis chronic neutrophilic leukemia de novo myelodysplastic syndromes disseminated neuroblastoma myelodysplastic/myeloproliferative neoplasm, unclassifiable poor prognosis metastatic gestational trophoblastic tumor previously treated childhood rhabdomyosarcoma previously treated myelodysplastic syndromes recurrent wilms tumor and other childhood kidney tumors recurrent childhood rhabdomyosarcoma recurrent neuroblastoma recurrent ovarian epithelial cancer recurrent ovarian germ cell tumor recurrent malignant testicular germ cell tumor secondary myelodysplastic syndromes stage i multiple myeloma stage ii multiple myeloma stage iii multiple myeloma stage ii ovarian epithelial cancer stage iii ovarian epithelial cancer stage iv ovarian epithelial cancer stage iii malignant testicular germ cell tumor stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer refractory multiple myeloma